Ferroptosis Role in the Pathophysiology of Systemic Lupus Erythematosus
Recruiting · NCT07260942 · Interventional (participants receive a specific treatment) · Lead sponsor: University Hospital, Bordeaux
View the official record on ClinicalTrials.gov →Interventions studied
blood sample
What this trial is about
The study aims at defining the role of ferroptosis s in the physiopathology of systemic lupus erythematosus (SLE). Ferroptosis (phenomenon of cellular death regulated by iron) is a metabolic pathway potentially implicated in SLE with potential for the discovery of new therapeutic strategies.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- age ≥ 18 years;
- diagnosis of systemic lupus erythematosus;
- being affiliated to health insurance, willing to participate and to sign informed consent;
- control group : patients with a diagnosis of rheumatoid arthritis or an inflammatory bowel disease.
Exclusion criteria
- pregnant or breastfeeding women;
- patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).
Where it is running
1 location listed.
- CHU de Bordeaux - service de rhumatologie - Bordeaux, France